FHTX vs. RAPP, SPRY, SYRE, UPB, CRON, NBTX, VALN, PGEN, RLAY, and MNMD
Should you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include Rapport Therapeutics (RAPP), ARS Pharmaceuticals (SPRY), Spyre Therapeutics (SYRE), Upstream Bio (UPB), Cronos Group (CRON), Nanobiotix (NBTX), Valneva (VALN), Precigen (PGEN), Relay Therapeutics (RLAY), and Mind Medicine (MindMed) (MNMD). These companies are all part of the "pharmaceutical products" industry.
Foghorn Therapeutics vs. Its Competitors
Rapport Therapeutics (NASDAQ:RAPP) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.
61.6% of Foghorn Therapeutics shares are held by institutional investors. 13.6% of Rapport Therapeutics shares are held by company insiders. Comparatively, 7.6% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Rapport Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.03, meaning that its stock price is 203% more volatile than the S&P 500.
In the previous week, Rapport Therapeutics had 2 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 6 mentions for Rapport Therapeutics and 4 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.96 beat Rapport Therapeutics' score of 0.76 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.
Rapport Therapeutics has higher earnings, but lower revenue than Foghorn Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.
Rapport Therapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -311.90%. Foghorn Therapeutics' return on equity of 0.00% beat Rapport Therapeutics' return on equity.
Rapport Therapeutics currently has a consensus target price of $35.33, suggesting a potential upside of 36.03%. Foghorn Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 161.22%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than Rapport Therapeutics.
Summary
Foghorn Therapeutics beats Rapport Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Foghorn Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Foghorn Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FHTX) was last updated on 10/14/2025 by MarketBeat.com Staff
